Rich Pharmaceuticals Inc. (fka RCHA)

[Moni001]

Did anyone else read this article ?


BEVERLY HILLS, CA, March 06, 2018 (GLOBE NEWSWIRE) -- Rich Pharmaceuticals, Inc. (OTC: RCHA), is a Biopharmaceutical Company focused on developing and commercializing innovative therapies in oncology using its study drug RP-323 (TPA). Multiple clinical studies have shown a significant increase in WBCs in patients with solid tumors who suffered from low WBCs counts, and the studies show that RP-323 plays a major part in the developmental processes that are vital to many patients’ treatment and recovery.

"In one of the studies with 52 patients, all but one of the patients treated with an infusion of our drug TPA increased the number of WBCs, some significantly. We know that WBCs are key to fighting disease and are vital to many patients' treatment and recovery," said Rich Pharmaceuticals CEO Ben Chang.

“Physicians become concerned if the number of WBCs fall or rise out of the healthy range since they help fight infections by attacking bacteria, viruses, and germs. Having a higher or lower number of WBCs may be an indication of an underlying condition,” explained Mr. Chang. “The ability to regulate WBC is a key element in immunotherapy. Immunotherapy is the treatment that stimulates your body’s own immune system to help fight cancer.”